Transdermal Drug Delivery Summary

Learning Objectives

• Understand transdermal drug delivery systems (TDDS): advantages, disadvantages, and components.

• Factors affecting skin permeability of drugs in TDDS.

• Application of Fick’s law of diffusion in drug diffusion through skin.

• Use and mechanisms of percutaneous absorption enhancers.

• Clinical information to advise patients using TDDS.

Overview of TDDS

• Transdermal Drug Delivery Systems (TDDS) represent a non-invasive pharmaceutical approach where active pharmaceutical ingredients are delivered across the skin barrier to achieve systemic circulation. This method leverages specially designed patches that allow for a controlled, sustained release of medication over an extended period, optimizing patient adherence and therapeutic outcomes.

• Primarily utilized for managing chronic conditions that benefit from steady-state drug levels, avoiding the peaks and troughs associated with conventional oral dosing.

Comparison: Topical vs. Transdermal Delivery

• Topical Delivery:

  • Focuses on localized therapeutic effects, with drug action primarily confined to the epidermis and superficial dermis.

  • Examples include creams, ointments, and gels applied for conditions like eczema or muscle pain. Minimal systemic absorption is generally desired and occurs.

• Transdermal Delivery (TDDS):

  • Aims for systemic absorption of the drug into the bloodstream, achieving therapeutic concentrations throughout the body.

  • Involves deeper and more controlled penetration through multiple skin layers and eventually into the dermal microcirculation, providing sustained drug levels over hours to days.

Advantages of TDDS

• Low proteolytic enzyme activity: The skin generally has fewer proteolytic enzymes compared to the gastrointestinal tract, leading to enhanced bioavailability for drugs susceptible to enzymatic degradation.

• Avoids hepatic first-pass metabolism: Drugs directly enter the systemic circulation via the dermal capillaries, bypassing the liver and preventing significant drug deactivation before reaching the target site, which improves drug efficacy and reduces required dosages.

• No gastrointestinal variability: Eliminates issues related to GI pH, enzymatic degradation, food-drug interactions, and motility variations, resulting in more consistent drug absorption and predictable plasma concentrations.

• Pain-free alternative to injections: Offers a non-invasive and comfortable option for patients who require parenteral administration, improving patient compliance, especially in pediatric or needle-averse populations.

• Continuous, sustained release: Provides a steady therapeutic drug level, minimizing fluctuations in plasma concentrations that can lead to side effects or sub-therapeutic levels. This is beneficial for drugs with narrow therapeutic windows.

• Flexible dosing with easy termination: Patients can easily initiate and terminate therapy by applying or removing the patch. The duration of action is determined by the patch design, allowing for simple adjustment of treatment periods.

Disadvantages of TDDS

• Limited to drugs with suitable physiochemical properties: Only a select range of drugs possess the necessary characteristics for effective transdermal absorption, such as an appropriate molecular weight (typically < 500 Da), adequate lipophilicity and hydrophilicity, and potent action at low doses.

• High melting point molecules exhibit poor permeability: Drugs with high melting points often have low solubility in both aqueous and lipid environments, hindering their ability to partition into and diffuse across the skin layers.

• Patches are not usually cuttable for dose flexibility: Most TDDS patches are designed with a specific drug release rate achieved through a controlled matrix or reservoir system. Cutting them can compromise the integrity of the rate-controlling mechanism, leading to unpredictable drug release, dose dumping, or loss of sterility.

• Significant absorption limitations due to the stratum corneum barrier: The outermost layer of the epidermis, the stratum corneum, is a formidable barrier composed of densely packed dead cells and lipids, severely limiting the percutaneous absorption of many drugs due to its low permeability.

• Potential for skin irritation and variable absorption rates: Adhesives, drug components, or permeation enhancers can cause local skin reactions like erythema, itching, or contact dermatitis. Absorption rates can also vary significantly based on individual skin hydration, age, body region, temperature, and disease states, leading to inconsistent drug delivery.

Candidate Drug Properties for TDDS

• Low molecular weight ($< 500 ext{ Da}$): Smaller molecules can more easily navigate through the tightly packed lipid bilayers and cellular structures of the stratum corneum.

• Adequate solubility in oil/water (amphiphilic): The drug needs to have sufficient solubility in both lipid (stratum corneum) and aqueous (epidermis/dermis) phases to partition effectively across these layers.

• Moderate partition coefficient ($1 < ext{Log P} < 3$): An optimal balance between lipophilicity and hydrophilicity is crucial. Too lipophilic, and the drug might get trapped in the stratum corneum; too hydrophilic, and it won't penetrate the lipid-rich barrier effectively.

• Low melting point ($< 200^ ext{o}C$): Compounds with lower melting points typically have higher solubilities and can readily dissolve in the skin lipids, facilitating permeation.

• Effective when delivered slowly and at low doses: Ideal candidates are potent drugs that achieve therapeutic effects with small amounts of drug delivered continuously, minimizing the total drug load needed for systemic absorption.

• Narrow therapeutic window: TDDS can maintain stable drug levels, reducing the risk of toxicity from high peaks and ensuring efficacy by avoiding sub-therapeutic troughs, which is critical for drugs with a narrow therapeutic index.

• Relatively short biological half-life (e.g., $< 10 ext{ hours}$): Drugs with short half-lives benefit greatly from continuous delivery, as it helps maintain steady-state concentrations without frequent dosing.

Skin Structure & Absorption Factors

1. Epidermis:

   • The outermost layer of the skin, primarily responsible for barrier function. Its main component, the stratum corneum, is a tough, non-living layer of flattened cells (corneocytes) embedded in a lipid matrix, acting as the primary rate-limiting step for most transdermal drug absorption. Thickness varies depending on body region, being thinner on the face and thicker on palms/soles.

   • $ext{Thickness: } 10-20 \, \mu\text{m}$ (excluding stratum lucidum and granulosum in some areas).

2. Dermis:

   • Located beneath the epidermis, it is a highly vascularized and innervated layer containing connective tissue, hair follicles, sweat glands, and sebaceous glands.

   • Once a drug penetrates the epidermis, it rapidly enters the rich capillary network in the dermis, facilitating systemic absorption. It plays a crucial role in distributing the drug throughout the body.

3. Hypodermis (Subcutaneous Tissue):

   • The innermost layer, primarily composed of adipose tissue. While less of a barrier, its fatty composition can serve as a potential depot for highly lipophilic drugs, affecting their sustained release profile. The extent of vascularization here is lower than in the dermis.

Routes of Drug Permeation

• Transepidermal Route: This is the principal pathway for most drugs, involving two sub-routes through the stratum corneum:

  • Transcellular (Intracellular) Route: Drugs pass directly through the corneocytes, penetrating their lipid-rich cell membranes and cytoplasm. This route is typically followed by very lipophilic drugs.

  • Intercellular (Paracellular) Route: Drugs travel through the lipid matrix between the corneocytes. This is the predominant pathway for most small, moderately lipophilic molecules.

• Transappendageal Route (Shunt Route): Involves permeation through skin appendages such as hair follicles and sebaceous glands, and sweat glands. While these routes offer a less resistant pathway, they represent a very small surface area (approximately $0.1\%$ of the total skin surface) and are generally considered minor pathways for overall drug absorption, though they can be significant for ionized or larger molecules or during the initial phase of absorption.

Factors Affecting Absorption

• Drug-Related Factors:

  • Molecular size/weight: Smaller molecules traverse the skin barrier more easily.

  • Partition coefficient: Optimal lipophilicity (Log P around 1-3) allows for sufficient partitioning into both lipid and aqueous phases of the skin.

  • Melting point: Lower melting points generally correlate with higher solubility and better skin permeation.

  • Ionization state (pKa): Only the unionized form of a drug can effectively penetrate the lipid-rich stratum corneum. The pH of skin surface (around 4.5-5.5) influences the ratio of ionized to unionized drug.

• Skin-Related and External Factors:

  • Skin hydration: Increased skin hydration swells corneocytes, loosening the lipid matrix and enhancing permeability. Occlusive patches significantly increase hydration.

  • Age: Pediatric and geriatric skin can be more permeable due to underdeveloped or degenerated stratum corneum, respectively.

  • Regional variation: Skin thickness and appendage density vary across body sites (e.g., thinner skin on the face absorbs more readily than thicker skin on the back).

  • Disease state: Dermatological conditions (e.g., psoriasis, eczema, burns) can compromise the skin barrier, leading to increased or altered drug absorption.

  • Temperature: Higher skin temperature increases drug diffusion rates and local blood flow, augmenting absorption.

  • Formulation type: The excipients, vehicle, and physical form of the drug in the patch (e.g., matrix vs. reservoir) significantly impact its release and subsequent absorption.

  • Enhancers: Chemical penetration enhancers or physical methods can temporarily disrupt the skin barrier to improve drug flux.

Fick’s Law of Diffusion

• Fick's Law of Diffusion describes the passive movement of drugs across a membrane (like the skin) from an area of higher concentration to an area of lower concentration. For transdermal systems, it is often applied to quantify the steady-state flux ($J$) of a drug through the skin: $J = (D \cdot K \cdot C_v) / h$ Where:

  • $J$ = Drug flux (rate of drug permeation per unit area, e.g., $\mu\text{g/cm}^2\text{/hr}$)

  • $D$ = Diffusion coefficient of the drug in the stratum corneum (relates to how fast the drug moves through the skin)

  • $K$ = Partition coefficient of the drug between the formulation and the stratum corneum (indicates how well the drug moves from the patch into the skin)

  • $C_v$ = Concentration of the drug in the vehicle or donor compartment (e.g., the patch)

  • $h$ = Thickness of the membrane, primarily the stratum corneum (the main barrier to diffusion)

• In practical terms, this law highlights that increasing the drug concentration in the patch, enhancing its ability to partition into the skin, or reducing the effective barrier thickness can increase the rate of drug absorption.

TDDS Components

1. Backing Layer:

   • The outermost protective layer, typically composed of occlusive, impermeable polymer films (e.g., polyester, polyurethane).

   • Functions: Protects the drug formulation from environmental factors (e.g., humidity, oxygen), provides mechanical support, prevents drug leakage, and is aesthetically pleasing. It should be comfortable and non-irritating.

2. Drug Reservoir/Matrix:

   • The core of the patch, holding the active pharmaceutical ingredient (API) along with excipients like solubilizers, permeation enhancers, and matrix formers.

   • In reservoir systems, the drug is contained in a liquid or gel compartment. In matrix systems, the drug is uniformly dispersed in a polymer adhesive layer. This component dictates the total drug available for delivery.

3. Rate-Controlling Membrane (if applicable):

   • Present in reservoir-type patches, this semi-permeable membrane (e.g., ethylene-vinyl acetate copolymer) precisely regulates the rate at which the drug is released from the reservoir to the skin's surface.

   • It ensures a consistent, sustained release profile, independent of the concentration gradient within the reservoir, after the initial burst.

4. Adhesive Layer:

   • A pressure-sensitive adhesive (e.g., polyisobutylene, polyacrylate, silicone) that ensures the patch adheres firmly to the skin for the entire wearing period.

   • It must be biocompatible, non-irritating, and allow for easy removal without leaving significant residue or causing discomfort. In many matrix systems, this layer also serves as the drug reservoir.

5. Release Liner:

   • A protective film (e.g., siliconized polyester or fluoropolymer-coated film) that is removed just before application.

   • Its primary function is to protect the adhesive layer and the drug formulation during storage and handling, ensuring product integrity until use.

Skin Penetration Enhancers

• Skin Penetration Enhancers (Permeation Enhancers) are agents used to temporarily and reversibly reduce the barrier function of the stratum corneum, thereby increasing the rate and extent of drug absorption.

• Examples:

  • Solvents: Dimethyl sulfoxide (DMSO), ethanol, methanol, isopropyl alcohol, propylene glycol, polyethylene glycols. These can extract lipid components, increase drug partitioning, and alter the stratum corneum's structure.

  • Surfactants: Sodium lauryl sulfate, poloxamers. They interact with skin lipids and proteins, increasing cell membrane fluidity and permeability.

  • Fatty acids and Alcohols: Oleic acid, lauryl alcohol. These can disrupt the intercellular lipid lamellae, creating more fluid pathways.

  • Urea: A humectant that enhances skin hydration and denatures keratin, loosening the stratum corneum structure.

  • Terpenes: Limonene, menthone. Can act as solvents and increase lipid fluidity.

• Mechanisms of Action:

  • Disruption of lipid packing: Enhancers interact with the intercellular lipids (e.g., ceramides, cholesterol, fatty acids) in the stratum corneum, altering their ordered structure, increasing fluidity, and creating more permeable pathways.

  • Enhanced hydration of the stratum corneum: Humectants (like urea, propylene glycol) draw water into the stratum corneum, causing it to swell and 'open up' the tightly packed structure, reducing its resistance.

  • Interaction with intracellular proteins: Some enhancers can denature or disrupt keratin and other proteins within the corneocytes, further weakening the barrier.

  • Increasing drug solubility and partitioning: Enhancers can improve the thermodynamic activity of the drug within the formulation and facilitate its partitioning into the skin.

Advanced Methods of Drug Delivery

• Microneedles:

  • Involve arrays of microscopic needles (typically $10-1000 \, \mu\text{m}$ in length) that painlessly pierce the stratum corneum to create transient micro-channels in the epidermis.

  • These micro-channels bypass the primary barrier, allowing for direct delivery of both small molecules and macromolecules (e.g., insulin, vaccines) that traditionally cannot penetrate the skin.

• Iontophoresis:

  • A non-invasive technique that uses a low-level electric current to drive ionized drug molecules across the skin.

  • The principal mechanism is electromigration (movement of charged ions due to an electric field), augmented by electroosmosis (bulk flow of solvent). It is particularly useful for delivering charged, water-soluble drugs.

• Phonophoresis (Sonophoresis):

  • Utilizes low-frequency ultrasound waves (typically $20 \text{ kHz}$ to $16 \text{ MHz}$) to enhance the percutaneous absorption of drugs.

  • The mechanical vibrations and cavitation (formation and collapse of microbubbles) induced by ultrasound create transient pores in the stratum corneum, increasing its permeability. It can deliver both small and large molecules.

Clinical Applications

• TDDS are widely used across various therapeutic areas due to their advantages.

• Contraception: Estrogen and progestin patches (e.g., Xulane) provide hormonal contraception.

• Hormone Replacement Therapy (HRT): Estrogen patches (e.g., Estraderm, Vivelle-Dot) for menopausal symptoms.

• Smoking Cessation: Nicotine patches (e.g., Nicoderm CQ) deliver controlled doses of nicotine to reduce withdrawal symptoms.

• Pain Management: Fentanyl patches (e.g., Duragesic) for chronic severe pain; lidocaine patches (e.g., Lidoderm) for localized neuropathic pain.

• Cardiovascular Conditions: Nitroglycerin patches (e.g., Minitran) for angina pectoris; clonidine patches (e.g., Catapres-TTS) for hypertension.

• Motion Sickness: Scopolamine patches (e.g., Transderm Scop) for preventing nausea and vomiting.

• Neurological Disorders: Rotigotine (e.g., Neupro) for Parkinson's disease and Restless Legs Syndrome.

Pharmacist Counseling for TDDS

• Pharmacists play a critical role in educating patients on the correct use and potential issues with TDDS to ensure optimal therapeutic outcomes and safety.

• Comprehensive Application Instructions:

  • Site Selection: Advise patients to apply patches to clean, dry, hairless skin on specific recommended body areas (often upper arm, torso, or hip), avoiding areas with cuts, rashes, or irritation.

  • Preparation: Ensure the skin is free of lotions, oils, or powder, which can impair adhesion or absorption.

  • Application: Press firmly for at least 10-30 seconds to ensure full contact.

  • Hand Hygiene: Wash hands thoroughly before and after application.

• Safety Precautions and General Use:

  • Avoiding Cutting Patches: Emphasize that cutting a patch can disrupt its controlled release system, leading to dose dumping or loss of efficacy and should rarely be done unless explicitly stated by the manufacturer.

  • Rotating Application Sites: Instruct patients to rotate application sites to prevent skin irritation and minimize the risk of saturation at one site, which can affect absorption. Do not reapply to the same spot for at least a week.

  • Monitoring for Irritation: Advise patients to check the application site daily for redness, itching, swelling, or rash. If severe irritation occurs, the patch should be removed, and a healthcare professional consulted.

  • Adherence: Reinforce that patches must remain on for the prescribed duration. If a patch falls off, advise on reapplication or applying a new patch.

  • Heat Exposure: Warn against exposing patches to external heat sources (e.g., heating pads, electric blankets, hot tubs, saunas) as this can increase drug absorption rapidly, potentially leading to overdose (especially critical for opioids like fentanyl).

  • MRI Compatibility: Caution patients to remove patches before an MRI scan, as some patches contain metallic components that can cause burns.

• Disposal Instructions:

  • Stress the importance of proper disposal, especially for potent drugs (e.g., opioids).

  • Patches should typically be folded sticky sides together and flushed down the toilet or disposed of in a secure waste container (check specific drug instructions regarding flushing). This prevents accidental exposure to children or pets.

• Counseling on Patch Efficacy and Risk Management:

  • Explain the expected onset and duration of action.

  • Discuss potential side effects beyond skin irritation (e.g., dizziness with nitroglycerin, nausea with scopolamine).

  • Advise on what to do if a dose is missed or if symptoms worsen.

  • Highlight the importance of not exceeding the prescribed dosage or